Presentation on theme: "Patent Litigation in India"— Presentation transcript:
1 Patent Litigation in India Pravin AnandAnand And AnandMIP International Patent Forum 2011April 5, 2011, London
2 The Challenges… First, a weak Patent Law Pre and post grant oppositions (Span case)Rigid deadlines (4)Section 3(d) - NovartisSection 8 - ChemturaWorking requirements , Compulsory licenceSection 39
3 The Challenges… Second, Generics, Copyleft, open-source aggressive: Parliamentary ForumsJudge trainingPress/BlogsNo counter measures by innovators
4 The Challenges… Third, top ten filers are chemistry patents World trend: top filers are IT companiesBeing an IT Power, ironic that Chemistry leadsGenerics – very patent savvy..
5 The Changes… 2005 Patent Amendments CPC – Streamlining Processes Supreme Court – 4 month orders (20 in 2010)Delhi High Court – 70% IP casesDocket ManagementOld order – 5 to 10 yearsToday – possibly 6 months to one year
7 Remedies Revolution Ex parte injunctions – before launch “status quo” Expedited trial preferredAnton Piller, Mareva InjunctionsJohn Doe OrdersDamages : Punitive / Exemplary (65 orders)
8 Time Inc vs. Lokesh Srivastava Red Border contributed to finding of dishonestyPunitive/ exemplary damages granted for the first time
9 Strategies Design action before launch Emphasis on original documents Issues : Document : Witness analysis – cannot miss the document window in fast trackExpert evidence of great value ( average – 2 witnesses per side, 6 hours cross, 150 ques)Emphasis on original documentsSection 65 – Secondary evidenceSection 65 B – Internet downloads
10 Strategies Invalidation before IPAB or counter claim before High Court IPAB slowHigh Court FastMay avoid cease & desist noticeAmendments allowed - infringement actionor after invalidation
11 StrategiesJudges Rely on foreign case law – favorable decisions elsewhere help – gestalt perceptionjudges often, a third forceGenerics look at prosecution histories all over – EPO highly respectedSuppression –big cause for failure - overstate
12 Strategies Demystify the science Use the defendants patent applications for estoppel argumentsHighlight Public Interest, pricing, patient access, investment in drug developmentAvoid Interim – move to Fast track
13 Cases Novartis Gleevec Supreme Court (19th April) Roche vs Cipla – final Arguments (April)GSK vs Union of India – writ quashed publicationUnited Phosphorus – pesticide formulation – suit decreed 34 days20 other suits of BMS, Sanofi Aventis, Scherring Plough etc likely to conclude in 2011
14 Conclusions Despite the weak legislation, major positive changes Bulk decisions in 2011 will show the long lasting trendsOther high courts may be positively impacted – time will tell..